Items where contributor is "Matter-Walstra, Klazien Wietske"
Matter-Walstra, K. W. and Greiner, M. and Cusini, A. and Schiesser, M. and Ledergerber, B. and Fehr, T. and Mueller, N. J.. (2015) Stringent adherence to a cytomegalovirus-prevention protocol is associated with reduced overall costs in the first 6 months after kidney transplantation. Transplant infectious disease, Vol. 17, H. 3. S. 342-349.
Matter-Walstra, K. and Achermann, R. and Rapold, R. and Klingbiel, D. and Bordoni, A. and Dehler, S. and Jundt, G. and Konzelmann, I. and Clough-Gorr, K. and Szucs, T. and Pestalozzi, B. and Schwenkglenks, M.. (2015) Cancer-Related Therapies at the End of Life in Hospitalized Cancer Patients from Four Swiss Cantons : SAKK 89/09. Oncology, Vol. 88, H. 1. S. 18-27.
Matter-Walstra, K. and Klingbiel, D. and Szucs, T. and Pestalozzi, B. C. and Schwenkglenks, M.. (2014) Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied? PharmacoEconomics, Vol. 32, no. 6. S. 591-599.
Matter-Walstra, K. M. and Achermann, R. and Rapold, R. and Klingbiel, D. and Bordoni, A. and Dehler, S. and Jundt, G. and Konzelmann, I. and Clough-Gorr, K. and Szucs, T. and Schwenkglenks, M. and Pestalozzi, B. C.. (2014) Delivery of health care at the end of life in cancer patients of four swiss cantons : a retrospective database study (SAKK 89/09). BMC cancer, Vol. 14. S. 306-317.
Jakovljevic, Mihajlo and Gutzwiller, Florian S. and Schwenkglenks, Matthias and Milovanovic, Olivera and Rancic, Nemanja and Varjacic, Mirjana and Stojadinovic, Dobrivoje and Dagovic, Aleksandar and Matter-Walstra, Klazien. (2014) Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma. JBUON, 19 (3). pp. 1111-1120.
Matter-Walstra, Klazien and Joerger, Markus and Kühnel, Ursula and Szucs, Thomas and Pestalozzi, Bernhard and Schwenkglenks, Matthias. (2012) Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the swiss health care system. Value in health, Vol. 15, H. 1. S. 65-71.
Joerger, M. and Matter-Walstra, K. and Früh, M. and Kühnel, U. and Szucs, T. and Pestalozzi, B. and Schwenkglenks, M.. (2011) Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer : a cost-utility analysis. Annals of oncology, Vol. 22, H. 3. S. 567-74.
Matter-Walstra, K. W. and Dedes, K. J. and Schwenkglenks, M. and Brauchli, P. and Szucs, T. D. and Pestalozzi, B. C.. (2010) Trastuzumab beyond progression : a cost-utility analysis. Annals of oncology, Vol. 21, H. 11. S. 2161-2168.
Dedes, Konstantin J. and Matter-Walstra, Klazien and Schwenkglenks, Matthias and Pestalozzi, Bernhard C. and Fink, Daniel and Brauchli, Peter and Szucs, Thomas D.. (2009) Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer : an economic evaluation. EJC : European journal of cancer, Vol. 45, H. 8. S. 1397-1406.
Walstra, K. and Gratwohl, A. and Riederer, I. and Speck, B.. (1985) B/T cell ratio of rabbit peripheral blood lymphocytes : influence of separation technique on results. Journal of immunological methods, Vol. 79, H. 1. S. 143-147.